Psychostimulants and vesicle trafficking: A novel mechanism and therapeutic implications

  • Hanson G
  • Sandoval V
  • Riddle E
 et al. 
  • 16

    Readers

    Mendeley users who have this article in their library.
  • 29

    Citations

    Citations of this article.

Abstract

The monoamine vesicular transporter 2 (VMAT-2) has been associated with dopamine (DA) sequestration and protection against neurodegeneration caused by the intracellular oxidation of this monoamine. The data presented herein suggest that methylphenidate treatment enhances the amount of VMAT-2 protein and possibly its activity in the presynaptic cytosol, where it is able to increase the sequestration of DA and likely protect against its instability. In contrast, methamphetamine (METH) has an opposite effect on cytosolic VMAT-2 resulting in degradation of DA terminals. The fact that posttreatment of methylphenidate after a neurotoxic regimen of METH protects against resulting loss of DA parameters suggests that treatment with methylphenidate, or other DA transporter blockers, may be protective against degenerative disorders of DA pathways, such as Parkinson's disease.

Author-supplied keywords

  • Degenerative disorders
  • Dopamine
  • Methamphetamine
  • Methylphenidate
  • Neurodegeneration
  • VMAT-2
  • Vesicular transporter 2

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Glen R. Hanson

  • Veronica Sandoval

  • Evan Riddle

  • Annette E. Fleckenstein

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free